Importance of B-Type Natriuretic Peptide in the Detection of Patients With Structural Heart Disease in a Primary Care Setting
-
- Fujimoto Wataru
- Division of Cardiovascular Medicine, Hyogo Prefectural Awaji Medical Center Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
-
- Odajima Susumu
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
-
- Okamoto Hiroshi
- Okamoto Cardiovascular Clinic
-
- Iwasaki Masamichi
- Division of Cardiovascular Medicine, Hyogo Prefectural Awaji Medical Center
-
- Nagao Manabu
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
-
- Konishi Akihide
- Clinical and Translational Research Center, Kobe University Hospital
-
- Shinohara Masakazu
- Division of Molecular Epidemiology, Kobe University Graduate School of Medicine
-
- Toh Ryuji
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
-
- Okuda Masanori
- Division of Cardiovascular Medicine, Hyogo Prefectural Awaji Medical Center
-
- Hirata Ken-ichi
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
-
- Tanaka Hidekazu
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
この論文をさがす
説明
<p>Background: Early detection and intervention for preclinical heart failure (HF) are crucial for restraining the potential increase in patients with HF. Thus, we designed and conducted a single-center retrospective cohort study to confirm the efficacy of B-type natriuretic peptide (BNP) for the early detection of preclinical HF in a primary care setting.</p><p>Methods and Results: We investigated 477 patients with no prior diagnosis of HF who were under the care of general practitioners. These patients were categorized into 4 groups based on BNP concentrations: Category 1, 0 pg/mL≤BNP≤35 pg/mL; Category 2, 35 pg/mL<BNP≤100 pg/mL; Category 3, 100 pg/mL<BNP≤200 pg/mL; and Category 4, BNP >200 pg/mL. There was a marked and statistically significant increase in the prevalence of preclinical HF with increasing BNP categories: 19.9%, 57.9%, 87.5%, and 96.0% in Categories 1, 2, 3, and 4, respectively. Compared with Category 1, the odds ratio of preclinical HF in Categories 2, 3, and 4 was determined to be 5.56 (95% confidence interval [CI] 3.57–8.67), 23.70 (95% CI 8.91–63.11), and 171.77 (95% CI 10.31–2,861.93), respectively.</p><p>Conclusions: Measuring BNP is a valuable tool for the early detection of preclinical HF in primary care settings. Proactive testing in patients at high risk of HF could play a crucial role in addressing the impending HF pandemic.</p>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 88 (5), 732-739, 2024-04-25
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390018451149402368
-
- NII書誌ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- HANDLE
- 20.500.14094/0100490210
-
- NDL書誌ID
- 033472985
-
- PubMed
- 38369348
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- IRDB
- NDL
- Crossref
- PubMed
-
- 抄録ライセンスフラグ
- 使用不可